Peter B. Bach

Chief Medical Officer

Peter B. Bach is the chief medical officer of Delfi Diagnostics. He was previously director of the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center.

Latest

A woman, suffering from Alzheimer's dese

Bloomberg Opinion

Medicare Needs to Test the New Alzheimer’s Drug Before Paying

For now, Aduhelm should be given only to beneficiaries who volunteer for a clinical trial.

January 3, 2022

January 3, 2022

OpinionPeter B. Bach and Rita F. Redberg

Medicare Needs to Test the New Alzheimer’s Drug Before Paying

For now, Aduhelm should be given only to beneficiaries who volunteer for a clinical trial.

A woman, suffering from Alzheimer's dese

June 15, 2021

June 15, 2021

OpinionPeter B. Bach and Craig Garthwaite

Medicare Must Study Unproven, Expensive Alzheimer’s Drug

Taxpayers and patients cannot afford to pay a high price for a treatment not known to be effective.

A nurse holds the hands of a person suff

September 29, 2020

September 29, 2020

OpinionPeter B. Bach

Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle

Pharmaceutical companies, on the other hand, would stand to make a lot more money.

President Trump Signs Executive Orders On Lowering Drug Prices

July 13, 2020

July 13, 2020

OpinionPeter B. Bach

U.S. Hospitals Need to Study How Well Remdesivir Really Works

With only limited evidence of effectiveness, the drug should be put to a large clinical trial.

GERMANY-HEALTH-VIRUS

March 17, 2020

March 17, 2020

OpinionPeter B. Bach and Mark Trusheim

U.S. Should Buy Coronavirus Vaccines Before They’re Invented

To ensure a reasonable price, take bids from drugmakers now.

Doctors Offer Drive-Thru Flu Shot Clinic

October 31, 2019

October 31, 2019

OpinionPeter B. Bach

Pelosi Calls Pharma’s Bluff on Drug Prices

Allowing Medicare to negotiate with drugmakers would barely slow the pace of innovation.

Her plan would not destroy innovation.

May 24, 2019

May 24, 2019

OpinionPeter B. Bach

No Miracle Drug Should Cost $2.1 Million

Congress helped create the ‘orphan drug’ problem and can fix it by demanding that prices reflect benefits.

SPAIN-HEALTH-EXOSKELETON

May 1, 2018

May 1, 2018

OpinionPeter B. Bach

Medicaid Is Right to Demand Lower Drug Prices

New York State can’t afford $250,000 a year for one cystic fibrosis medicine.

One drug that can help patients breathe costs too much.